Rheumatoid Arthritis

      #polyrefractory #RA
      =
      failed all classes in #rheumatoid #arthritis
      +inflammatory #arthritis
      Longer disease duration
      Lat

      Janet Pope Janetbirdope

      6 months ago
      #polyrefractory #RA = failed all classes in #rheumatoid #arthritis +inflammatory #arthritis Longer disease duration Late RA Rx +power Doppler in POCUS ⬆️no refractory BMI Fibromyalgia - pain ⬇️SJC, less DAS , rapid X-ray progression #EULAR2025 @RheumNow #D2T #RA https://t.co/1sPwf3Qa3m
      #Cancer is not ⬆️in JAKi vs #bDMARDs in
      #rheumatoid #arthritis
      When adjusted for #confounders

      #JAKPOT data

      Now y

      Janet Pope Janetbirdope

      6 months ago
      #Cancer is not ⬆️in JAKi vs #bDMARDs in #rheumatoid #arthritis When adjusted for #confounders #JAKPOT data Now you see it (unadjusted ⬆️risk) Now you don’t (adjusted =#malignancy) JAKi vs bDMARDs in RA EULAR2025 @RheumNow @eular_org #JAK it out! new perspective on JAKi https://t.co/wCQ3dHNAVa
      #D2T #RA ~20%

      #Polyrefractory 3%

      Many reasons for d/c ing #Rx - D2T
      AEs
      Intolerance
      Chronic pain
      Etc

      My approach is

      Janet Pope Janetbirdope

      6 months ago
      #D2T #RA ~20% #Polyrefractory 3% Many reasons for d/c ing #Rx - D2T AEs Intolerance Chronic pain Etc My approach is different depending on reasons why drugs were d/c Ie ?obj inflammation vs pain or intolerance @RheumNow @eular_org #EULAR2025 #whatmakes D2T RA difficult https://t.co/AL6TMVJIk9
      Would you use #CAR-T in #polyrefractory #RA
      #EULAR2025 @RheumNow @eular_org

      Janet Pope Janetbirdope

      6 months ago
      Would you use #CAR-T in #polyrefractory #RA #EULAR2025 @RheumNow @eular_org
      POS0150: From 12 RA registries, JAKi starts fell by ~13% after FDA safety alerts.
      Tofa & bari took biggest hits; upa

      Jiha Lee JihaRheum

      6 months ago
      POS0150: From 12 RA registries, JAKi starts fell by ~13% after FDA safety alerts. Tofa & bari took biggest hits; upa growth slowed but offset losses. Real-world prescribing adapts—but doesn’t abandon. @RheumNow #EULAR2025 https://t.co/QZ5haW2vhX
      Ultrasound for ILD detection in RA 🫁

      Sens 88.6
      Spe 92.8
      NPV 91.4
      PPV 90.7

      While if abnormal or high suspicion, HRC

      Aurelie Najm AurelieRheumo

      6 months ago
      Ultrasound for ILD detection in RA 🫁 Sens 88.6 Spe 92.8 NPV 91.4 PPV 90.7 While if abnormal or high suspicion, HRCT should be the reference, I see this as an interesting tool in clinics for quick screening POS0180 #EULAR2025 @RheumNow https://t.co/pUy0ki7Y6S
      #HOT topic

      Lung 🫁 #ultrasound for #RA #ILD
      #LUS B lines vs HRCT

      Single site 🇫🇷 study

      V sensitive & spe

      Janet Pope Janetbirdope

      6 months ago
      #HOT topic Lung 🫁 #ultrasound for #RA #ILD #LUS B lines vs HRCT Single site 🇫🇷 study V sensitive & specific 🤔needs standardization & comparison in other groups Abst#POS-180 #EULAR2025 @RheumNow @eular_org https://t.co/PwGE4rgk40
      Software enhances treat to target outcomes for #RA GoTreatIT
      P0S0750 ##EULAR2025 @RheumNow https://t.co/GpihWr5KLA

      Bella Mehta bella_mehta

      6 months ago
      Software enhances treat to target outcomes for #RA GoTreatIT P0S0750 ##EULAR2025 @RheumNow https://t.co/GpihWr5KLA
      Does having a synovitis in a specific joint predicts Rx damage in that same joint?

      Yes

      Can US synovitis predict Rx pro

      Aurelie Najm AurelieRheumo

      6 months ago
      Does having a synovitis in a specific joint predicts Rx damage in that same joint? Yes Can US synovitis predict Rx progression better than clinical synovitis at the joint level? Not really At 1 year, only US synovitis is, both B-mode and Doppler ass w/ Rx prog, in particular https://t.co/Wu6dDqIUYn
      Tenosynovitis of 5th compartment independently associated w/ D2T RA in a cohort of 90+ pts compared to established RA
      Er

      Aurelie Najm AurelieRheumo

      6 months ago
      Tenosynovitis of 5th compartment independently associated w/ D2T RA in a cohort of 90+ pts compared to established RA Erosions, Tenosynovitis and Synovitis non associated with D2T phenotype It’d be interesting to see if this could predict D2T evolution in early RA pts POS0185 https://t.co/faruOr3HhJ
      Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data
      6 months ago
      New dual-action RA drug?
      OP0193: CPL’116 targets both JAK & ROCK.
      In 12-wk RCT, highest dose improved DAS28-CRP,

      Jiha Lee JihaRheum

      6 months ago
      New dual-action RA drug? OP0193: CPL’116 targets both JAK & ROCK. In 12-wk RCT, highest dose improved DAS28-CRP, joint counts & pain, with clean labs. Is this a future option for RA-ILD or patients with comorbid CVD risk? #EULAR2025 @RheumNow
      Ph 2 RCT CPL'116 dual inhibition JAK/ROCK
      106 MTX IR pts
      wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs.

      Aurelie Najm AurelieRheumo

      6 months ago
      Ph 2 RCT CPL'116 dual inhibition JAK/ROCK 106 MTX IR pts wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs. PBO 75% >= AEs, SAE 2: 1 MI, 1 bladder cancer Authors suggest absence of lipids/LFTs disruption compared to other JAKs Ph3 is awaited!! #OP0193 #EULAR2025 https://t.co/TnnM410LfM
      Combination of LEF and MTX in RA: Yay or Nay?

      #EULAR2025 @RheumNow

      Aurelie Najm AurelieRheumo

      6 months ago
      Combination of LEF and MTX in RA: Yay or Nay? #EULAR2025 @RheumNow
      OP0195: MTX+LEF isn’t commonly used—but could it be a viable option after all?

      In >1,100 RA pts, no link to live

      Jiha Lee JihaRheum

      6 months ago
      OP0195: MTX+LEF isn’t commonly used—but could it be a viable option after all? In >1,100 RA pts, no link to liver fibrosis (FIB-4/APRI), modest ALT ↑, and fewer hospitalizations. real-world safety data worth a second look. @RheumNow #EULAR2025

      Catch up on Conference Podcasts

      ×